-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – INCB-53914
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry INCB-53914 Drug Details INCB-53914 is under development for the treatment of advanced hematological malignancies...
-
Product Insights
Serine-Threonine Protein Kinase Pim (Pim Kinase or PIM or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Serine/Threonine Protein Kinase Pim (Pim Kinase or PIM or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Serine/Threonine Protein Kinase Pim (Pim Kinase or PIM or EC 2.7.11.1) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of...
-
Product Insights
Candidiasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash. It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti-fungal drugs. The Candidiasis - drugs...
-
Product Insights
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Serine/Threonine Protein Kinase Pim 3 pipeline market research report provides comprehensive information on the Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players...
-
Product Insights
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The serine/threonine protein kinase pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted pipeline therapeutics report provides comprehensive information on the serine/threonine protein kinase pim 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides...
-
Product Insights
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Serine/Threonine Protein Kinase Pim 1 pipeline market research report provides comprehensive information on the Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved...
-
Product Insights
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report SerineThreonine Protein Kinase Pim 3 - Drugs in Development, 2021, outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA),...